A Randomized, Eight Week Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy.

Trial Profile

A Randomized, Eight Week Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Aliskiren/amlodipine; Amlodipine
  • Indications Essential hypertension
  • Focus Adverse reactions; Biomarker; Registrational
  • Most Recent Events

    • 27 Aug 2010 FDA approval of Tekamlo was based on clinical trial data involving more than 5000 patients, including data from this study, according to a Novartis media release.
    • 21 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Actual patient number (849) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top